Mirum Pharmaceuticals, Inc.
MIRM
|
$23.45
-1.68%
14K
|
Health Technology
(0.0% 1d) (-11.7% 1m) (-8.3% 1y) (0.0% 2d) (-0.7% 3d) (-3.0% 7d) (3.0% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 1,102,228,065
http://www.mirumpharma.com
Sec Filling | Patents | 33 employees
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
liver liver disease
add to watch list Paper trade email alert is off
Press-releases
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 11, 2024
Published: 2024-04-11 (Crawled : 07:00) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: -0.35%
H: 1.98%
C: 1.25%
nasdaq pharmaceuticals grants
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: -1.3%
H: 0.7%
C: 0.36%
pruritus positive livmarli
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SGMT | $3.95 -2.95% 54K
|
Health Technology
|
| O: 6.65%
H: 18.5%
C: 8.52%
IPSC | $2.785 -1.94% 27K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 1.58%
C: -9.48%
RPHM | $1.74 -1.7% 8.1K
|
Professional, Scientific, and T...
|
| O: -1.81%
H: 4.91%
C: 2.45%
XOMA | News | $24.25 320
|
Health Technology
|
| O: 1.09%
H: 3.51%
C: -4.27%
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: 0.04%
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: 1.49%
H: 2.98%
C: -0.43%
fda pruritus approval treatment livmarli
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - March 5, 2024
Published: 2024-03-05 (Crawled : 14:30) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: 0.17%
H: 1.04%
C: -2.54%
pharmaceuticals
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: -1.04%
H: 4.87%
C: 0.42%
livmarli
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
Published: 2024-02-21 (Crawled : 00:00) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: -0.45%
H: 1.28%
C: -2.31%
conference pharmaceuticals financial results
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 11, 2024
Published: 2024-01-11 (Crawled : 07:00) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: 0.04%
H: 3.88%
C: 2.32%
nasdaq pharmaceuticals grants
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
Published: 2024-01-08 (Crawled : 16:00) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: -1.39%
H: 0.43%
C: 0.21%
revenue pharmaceuticals
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 17:00) - biospace.com/
MIRM | $23.45 -1.68% 14K
|
Health Technology
|
| O: -0.07%
H: 0.97%
C: -2.0%
conference pharmaceuticals
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 73% | 27% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.445 90.13% 2.5M
|
Health Technology
SINT | $0.0588 57.64% 240M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
LRHC | News | $2.02 26.25% 230K
|
n/a
Last 48 Hours Insiders Buying
RELL | $10.0 1.42% 13K
|
Electronic Technology
|
13:30
IZEA | $2.53 4K
|
Technology Services
|
00:00
RKT P 383 | $11.61 2.02% 96K
|
Finance
|
22:30
CTRN P 18090 | $22.34 -0.13% 8.1K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% 41K
|
Energy Minerals
|
21:00
NEOG P 10000 | $11.96 -1.48% 140K
|
Health Technology
|
16:30
RMCF | $3.53 360
|
Consumer Non-Durables
|
20:10